CSL's (ASX:CSL) influenza vaccine unit, Seqirus, has secured a contract to supply 15 million doses of a cell-based adjuvanted pandemic flu vaccine from its new Melbourne facility if a pandemic is declared by the World Health Organization, according to a Thursday report by the Australian Financial Review.

CSL Seqirus has previously had a contract with Canada, under which it was required to provide an egg-based influenza vaccine in the event of a pandemic, the report added.

The company's shares rose almost 2% in recent Thursday trade.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)